Cover Image

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience

Saved in:

Bibliographic Details
Main Authors:	Luigi Gargiulo (Author), Luciano Ibba (Author), Carlo Alberto Vignoli (Author), Paola Facheris (Author), Mario Valenti (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
Format:	Book
Published:	Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience
by: Luigi Gargiulo, et al.
Published: (2023)

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study
by: Luigi Gargiulo, et al.
Published: (2023)

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients
by: Francesco Piscazzi, et al.
Published: (2023)

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
by: Luigi Gargiulo, et al.
Published: (2024)

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals
by: Giovanni Paolino, et al.
Published: (2024)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024)

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study
by: Luciano Ibba, et al.
Published: (2023)

Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series
by: Luigi Gargiulo, et al.
Published: (2023)

Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience
by: Silvia Ferrucci, et al.
Published: (2023)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024)

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024)

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis
by: Francesca Caroppo, et al.
Published: (2024)

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab
by: Annunziata Dattola, et al.
Published: (2024)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021)

Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series
by: Patrícia Amoedo, et al.
Published: (2024)

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis
by: Galina Balakirski, et al.
Published: (2023)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024)

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
by: Luciano Ibba, et al.
Published: (2023)

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
by: Luigi Gargiulo, et al.
Published: (2024)

Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
by: Andrea Cortese, et al.
Published: (2023)

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
by: Luigi Gargiulo, et al.
Published: (2024)

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
by: Gioele Ghezzi, et al.
Published: (2024)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
by: Kelly KA, et al.
Published: (2022)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
by: L. Mastorino, et al.
Published: (2023)

Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
by: Luigi Gargiulo, et al.
Published: (2023)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
by: Moennig E, et al.
Published: (2022)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
by: Maxim A.X. Tollenaere, et al.
Published: (2021)

Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
by: Carlo Alberto Vignoli, et al.
Published: (2023)

Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report
by: Ilaria Trave, et al.
Published: (2024)

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
by: Kaidi Zhao, et al.
Published: (2024)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023)

Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report
by: Mario Valenti, et al.
Published: (2024)

New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
by: Eric L. Simpson, et al.
Published: (2018)

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
by: Adelaide A. Hebert, et al.
Published: (2024)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024)